Clinical trial · Interventional
Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone
Multicenter, Randomised Open Trial Comparing the Efficacy of a Medical Treatment With Sandostatin LP 30 mg Performed Before Surgery to a Prime Line transsphenoïdal Surgery in Previously Untreated Acromegalic Patients With Either a Micro or a Macro Pituitary Adenoma
NCT01029275CI-TRIAL-00015279SAPOROcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the interest of a six month pre-operative treatment with a long-acting somatostatin analog (Sandostatin LP) versus surgery alone in patients with a pituitary adenoma responsible for acromegaly.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acromegaly | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pre-treatment with octreotide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Arm A
- description
- pre-operative medical treatment with Sandostatin
- interventionNames
- Drug: Pre-treatment with octreotide
- type
- NO_INTERVENTION
- label
- Arm B
- description
- pituitary surgery as a first line treatment
Primary outcomes (1)
- measure
- IGF1 plasma levels
- timeFrame
- 3 months and 12 months after transphenoidal surgery
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * men and women * 18-80 years old * untreated acromegaly * unsuppressed GH secretion after a glucose load and elevated IGF-1 plasma levels * presence of a pituitary adenoma on MRI * informed consent given. Exclusion Criteria: * acromegaly previously treated * contraindication to pituitary surgery * associated hyperprolactinemia above 200 ng/ml * visual field defect needing rapid transsphenoidal surgery * contraindication to a treatment with octreotide
References
Publications (0)
Data not yet available
No reference posted for this study.